|
Index | - | P/E | - | EPS (ttm) | - | Insider Own | 63.79% | Shs Outstand | 8.91M | Perf Week | 8.25% |
Market Cap | 56.13M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 0.21M | Perf Month | 28.31% |
Income | - | PEG | - | EPS next Q | - | Inst Own | 12.22% | Short Float | 13.30% | Perf Quarter | 37.25% |
Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.10 | Perf Half Y | - |
Book/sh | - | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | - |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 3.82 - 7.85 | Perf YTD | 40.94% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -19.75% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 64.92% | ATR | 0.73 |
Employees | - | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 60.99 | Volatility | 15.84% 14.45% |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.69 | Prev Close | 6.50 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 290.28K | Price | 6.30 |
Recom | - | SMA20 | 17.59% | SMA50 | 30.39% | SMA200 | 29.19% | Volume | 201,965 | Change | -3.08% |
![]() | ||||||||||||||||||||
![]() | ||||||||||||||||||||
|
||||||||||||||||||||
![]() | ||||||||||||||||||||
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of products for the treatment of pain in Israel. It develops PRF-110, a product based on local anesthetic ropivacaine, which completed Phase II clinical study in hernia repair. The company was founded in 2007 and is headquartered in Herzeliya, Israel. | ||||||||||||||||||||
![]() | ||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite